Amylyx Pharmaceuticals (AMLX) Enterprise Value (2022 - 2026)

Amylyx Pharmaceuticals has reported Enterprise Value for 5 years, with the latest figure at $1.7 billion in Q2 2026.

• On a quarterly basis, Enterprise Value rose 347.8% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 347.8% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 1118.56% from the prior year.
• Enterprise Value was $1.7 billion for Q2 2026 at Amylyx Pharmaceuticals, up from $1.3 billion in the prior quarter.
• The five-year high for Enterprise Value was $2.1 billion in Q4 2022, with the low at -$180.5 million in Q2 2024.
• Average Enterprise Value over 5 years is $811.8 million, with a median of $900.8 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value sank 116.47% in 2024, then soared 9425.45% in 2025.
• Over 5 years, Enterprise Value stood at $2.1 billion in 2022, then sank by 70.37% to $625.3 million in 2023, then sank by 86.74% to $82.9 million in 2024, then soared by 1118.56% to $1.0 billion in 2025, then surged by 73.14% to $1.7 billion in 2026.
• The last three Enterprise Value figures came in at $1.7 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.